Agreed! I think after the FDA-approval, 90-cents is conservative for starters. We still have that 97-cents wall to knockout before we could start thinking about a higher PPS breakout. But with strong revenues and net profit gains, it would sure pack a punch to knock the wall down.
Well- I appreciate you laying out your thought process on the matter - certainly logic to it and able to follow the train of thought - we shall see - if Elite can run to .97 on no ADT opioid on the market - $2 on a run is quite possible. We shall see.
The problem is that isn't how drug stocks work though in the currently painted scenario. Drug stocks move on approval not when the revenues actually come in, they trade on future prospects. The issue here is that if approval is a layup and revenues are sure to come, then people would be buying right now in droves. That is unless something else is making the buyers pause which is the case at the moment. Don't know what it is, but it's happening at the moment.